Antigenic differences between normal and malignant cells of the cancer patient form the rationale for clinical immunotherapeutic strategies. While the central nervous system has traditionally been thought of as an immune-privileged site, studies have been conducted that demonstrate the potential efficacy of immunotherapy in management of primary and secondary brain tumors. Immunization in patients with dendritic cells “fed” derivatives of tumor cells or transfected with tumor-RNA can result in the induction of tumor-specific CD8+ cytotoxic T-lymphocyte (CTL) responses against the patient’s malignant cells. In addition, work has been done involving regulation of Immune checkpoint inhibitors which are capable of blocking molecules involved in inhibiting immune cells that can result in a stimulation of the T-cell response against various tumors, including brain tumors. Although results of dendritic cell immunotherapy or checkpoint inhibitors have demonstrated promise in animal models, clinical trials have documented relatively short benefits or limited to a minority of treated patients. In many aggressive tumors, such as gliomas, progression is enabled by local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). Cytokine gene vaccine therapy involving IL-15 or IL-2 has also been shown in brain tumor animal models to stimulate a potent antitumor immune response and prolong survival.
In this Research Topic, we will welcome all types of articles addressing novel and innovative immunotherapy treatments for brain tumors.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Brain Tumors, Gliomas, Cytokine gene vaccine therapy, Immunotherapy, Angiogenesis, Check-point inhibitors, Dendritic cell therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Antigenic differences between normal and malignant cells of the cancer patient form the rationale for clinical immunotherapeutic strategies. While the central nervous system has traditionally been thought of as an immune-privileged site, studies have been conducted that demonstrate the potential efficacy of immunotherapy in management of primary and secondary brain tumors. Immunization in patients with dendritic cells “fed” derivatives of tumor cells or transfected with tumor-RNA can result in the induction of tumor-specific CD8+ cytotoxic T-lymphocyte (CTL) responses against the patient’s malignant cells. In addition, work has been done involving regulation of Immune checkpoint inhibitors which are capable of blocking molecules involved in inhibiting immune cells that can result in a stimulation of the T-cell response against various tumors, including brain tumors. Although results of dendritic cell immunotherapy or checkpoint inhibitors have demonstrated promise in animal models, clinical trials have documented relatively short benefits or limited to a minority of treated patients. In many aggressive tumors, such as gliomas, progression is enabled by local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). Cytokine gene vaccine therapy involving IL-15 or IL-2 has also been shown in brain tumor animal models to stimulate a potent antitumor immune response and prolong survival.
In this Research Topic, we will welcome all types of articles addressing novel and innovative immunotherapy treatments for brain tumors.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Brain Tumors, Gliomas, Cytokine gene vaccine therapy, Immunotherapy, Angiogenesis, Check-point inhibitors, Dendritic cell therapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.